Concepedia

Rod Humerickhouse

RH

87

Publications

18K

Citations

43

H-Index

1993

Active since

Affiliations

AbbVie (United States)(Current)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Peter MacCallum Cancer Centre

University of California San Diego

Rod Humerickhouse is an author at AbbVie (United States) specializing in medicine, oncology, and cancer research.

Top concepts

Publications per year

1993–2021

87

Publications

87

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

, , +11

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.8K citations · Full text

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1K citations · Full text

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 881 citations · Full text

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 840 citations · Full text

, , +11

Rows per page

1–5 of 87